Trial Profile
Safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin chronic hepatitis C virus infection patients with genotype 1 and 4: German Hepatitis C Registry study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 May 2018
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 18 May 2018 New trial record